MXPA04002490A - Interleucina-12 como adyuvante de vacuna veterinaria. - Google Patents

Interleucina-12 como adyuvante de vacuna veterinaria.

Info

Publication number
MXPA04002490A
MXPA04002490A MXPA04002490A MXPA04002490A MXPA04002490A MX PA04002490 A MXPA04002490 A MX PA04002490A MX PA04002490 A MXPA04002490 A MX PA04002490A MX PA04002490 A MXPA04002490 A MX PA04002490A MX PA04002490 A MXPA04002490 A MX PA04002490A
Authority
MX
Mexico
Prior art keywords
immunogenicity
enhancing
composition
immunoadjuvant
immunomodulator
Prior art date
Application number
MXPA04002490A
Other languages
English (en)
Inventor
Chu Hsien-Jue
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MXPA04002490A publication Critical patent/MXPA04002490A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invencion describe una composicion para incrementar la inmunogenicidad de una vacuna veterinaria que comprende una cantidad farmacologicamente efectiva de un inmunorregulador y un inmunoadyuvante. Ademas, la descripcion describe una composicion de vacuna que comprende una un cantidad inmunizante efectiva de un antigeno, inmunorregulador, un inmunoadyuvante y un portador farmaceuticamente aceptable. Las composiciones pueden contener opcionalmente adyuvantes convencionales secundarios o conservadores. La invencion ademas describe un metodo unico para intensificar o acelerar la inmunogenicidad de antigenos marginalmente seguros, inmunosupresores o debiles al administrarle a una especie aviar o de mamifero, una cantidad farmacologicamente efectiva de la composicion intensificadora de la inmunogenicidad o una cantidad inmunizante efectiva de la composicion de vacuna anteriormente mencionada.
MXPA04002490A 2001-09-17 2002-09-13 Interleucina-12 como adyuvante de vacuna veterinaria. MXPA04002490A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32284001P 2001-09-17 2001-09-17
US10/243,075 US20030129161A1 (en) 2001-09-17 2002-09-12 Interleukin-12 as a veterinary vaccine adjuvant
PCT/US2002/029229 WO2003024354A2 (en) 2001-09-17 2002-09-13 Interleukin-12 as a veterinary vaccine adjuvant

Publications (1)

Publication Number Publication Date
MXPA04002490A true MXPA04002490A (es) 2004-05-31

Family

ID=26935571

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04002490A MXPA04002490A (es) 2001-09-17 2002-09-13 Interleucina-12 como adyuvante de vacuna veterinaria.

Country Status (14)

Country Link
US (2) US20030129161A1 (es)
EP (1) EP1427349A4 (es)
JP (1) JP2005520786A (es)
KR (1) KR20040044942A (es)
CN (1) CN1555271A (es)
BR (1) BR0212556A (es)
CA (1) CA2457563A1 (es)
HR (1) HRP20040282A2 (es)
HU (1) HUP0500238A3 (es)
MX (1) MXPA04002490A (es)
NZ (1) NZ531526A (es)
PL (1) PL374123A1 (es)
WO (1) WO2003024354A2 (es)
YU (1) YU24004A (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7347996B1 (en) * 2002-06-26 2008-03-25 Intevert International B.V. Avian cytokines, such as IL-12, comprising a p40 and/or p35 subunit and vaccines
US20050089533A1 (en) * 2003-01-29 2005-04-28 Joseph Frantz Canine vaccines against Bordetella bronchiseptica
EP1708742A4 (en) * 2003-12-05 2008-11-05 Becton Dickinson Co METHOD FOR IMPROVING THE IMMUNE RESPONSE IN THE INTRADERMAL COMPARTMENT AND USEFUL LINKS THEREFOR
US20050202046A1 (en) * 2004-03-11 2005-09-15 Wyeth Canine vaccine for protection against ehrlichiosis
CN100425288C (zh) * 2005-01-28 2008-10-15 北京金迪克生物技术研究所 鼻腔喷雾型流感病毒灭活疫苗及其制备方法
KR100517114B1 (ko) * 2005-02-25 2005-09-27 주식회사 바이오리더스 폴리감마글루탐산을 함유하는 면역보강제 조성물
ATE499112T1 (de) 2005-09-01 2011-03-15 Celgene Corp Immunologische verwendungen von immunmodulatorischen verbindungen für einen impfstoff und therapie gegen infektionskrankheiten
US7682619B2 (en) * 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
AU2007343130C1 (en) 2006-12-27 2017-11-09 Zoetis Services Llc Methods of vaccine administration
KR100836745B1 (ko) * 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
CL2008001806A1 (es) * 2007-06-20 2008-09-05 Wyeth Corp Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion.
US8501190B2 (en) * 2007-06-22 2013-08-06 The University Of Guelph Vaccine against Clostridium perfringens
FR2922767B1 (fr) * 2007-10-24 2009-12-18 Seppic Sa Procede de preparation d'une composition vaccinale comprenant au moins un antigene et au moins un adjuvant.
ME01000B (me) 2007-11-06 2012-10-20 Zoetis Services Llc Živa vakcina avirulentne mycoplasma hyopneumoniae sa adjuvansom
US8273122B2 (en) 2008-06-23 2012-09-25 Abbott Medical Optics Inc. Pre-loaded IOL insertion system
CN105203755B (zh) 2009-11-20 2018-01-05 爱贝斯股份有限公司 用于检测埃里希体属抗体的肽、装置和方法
CA2800348C (en) * 2010-05-18 2020-07-21 Lena A. Basile Il-12 formulations for enhancing hematopoiesis
CN102908613A (zh) * 2011-08-04 2013-02-06 广州格拉姆生物科技有限公司 一种猪用免疫增强剂il-12b(p40)及其制备方法
JP6325553B2 (ja) 2012-10-11 2018-05-16 アバクシス， インコーポレイテッド エールリヒア抗体の検出のためのペプチド、デバイス、および方法
CN103028114A (zh) * 2012-12-28 2013-04-10 贵州大学 一种核酸疫苗、核酸疫苗免疫佐剂及制备方法
US9442112B2 (en) 2014-04-04 2016-09-13 Abaxis, Inc. Compositions and methods for identifying Ehrlichia species
CN104857511B (zh) * 2015-02-13 2018-03-30 浙江大学 含人参皂甙的疫苗稀释剂
WO2017041720A1 (zh) * 2015-09-09 2017-03-16 清华大学 作为高效的疫苗佐剂的甲羟戊酸通路的抑制剂

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047238A (en) * 1983-06-15 1991-09-10 American Home Products Corporation Adjuvants for vaccines
US4567042A (en) * 1983-06-15 1986-01-28 American Home Products Corporation Inactivated canine coronavirus vaccine
US5503841A (en) * 1985-09-20 1996-04-02 Cetus Oncology Corporation Human IL-2 as a vaccine adjuvant
US5643565A (en) * 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
US5266311A (en) * 1987-05-28 1993-11-30 Immunex Corporation Bovine interleukin-1α
US4894333A (en) * 1987-05-28 1990-01-16 Immunex Corporation Bovine interleukin-1α
US5106733A (en) * 1987-06-25 1992-04-21 Immunex Corporation Bovine granulocyte-macrophage colony stimulating factor
US5242686A (en) * 1990-11-07 1993-09-07 American Home Products Corporation Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
MY111829A (en) * 1994-05-10 2001-01-31 Zoetis W Llc Modified live brsv vaccine
ES2257744T3 (es) * 1994-10-05 2006-08-01 Vanderbilt University Interleuquina-12 como adyuvante para vacunas contra paramyxoviridae.
US5674483A (en) * 1995-01-31 1997-10-07 National Jewish Medical And Research Center Treatment for diseases involving inflammation
US5665347A (en) * 1995-02-02 1997-09-09 Genetics Institute IL-12 inhibition of B1 cell activity
DE69620877T2 (de) * 1995-02-06 2002-12-12 Genetics Inst Arzneimittelformulierungen für il-12
US5853714A (en) * 1995-03-27 1998-12-29 Genetics Institute, Inc. Method for purification of IL-12
US5820869A (en) * 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
US5972350A (en) * 1996-05-06 1999-10-26 Bayer Corporation Feline vaccines containing Chlamydia psittaci and method for making the same
ATE325621T1 (de) * 1996-05-31 2006-06-15 Nat Univ Ireland Maynooth Il-12 als adjuvanz für bordetella pertussis impfstoffe
GB9712347D0 (en) * 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
CA2243730C (en) * 1997-07-29 2009-12-22 Akzo Nobel N.V. Streptococcus equi vaccine
WO1999040937A2 (en) * 1998-02-12 1999-08-19 American Cyanamid Company Vaccines comprising interleukin-12 and respiratory syncytial viral antigens
US5985264A (en) * 1998-03-05 1999-11-16 The Medical College Of Ohio IL-12 Stimulation of Neonatal immunity
US6375944B1 (en) * 1998-09-25 2002-04-23 The Wistar Institute Of Anatomy And Biology Methods and compositions for enhancing the immunostimulatory effect of interleukin-12
US6458942B1 (en) * 1998-11-30 2002-10-01 Research Development Foundation 28-kDa immunoreactive protein gene of Ehrlichia canis and uses thereof
AU6683400A (en) * 1999-07-08 2001-01-30 Mologen Forschungs-, Entwicklungs- Und Vertriebs Gmbh Vaccine against lentiviral infections, such as the feline immune deficiency virus of the cat

Also Published As

Publication number Publication date
HUP0500238A3 (en) 2009-01-28
EP1427349A4 (en) 2006-01-11
BR0212556A (pt) 2007-04-17
WO2003024354A2 (en) 2003-03-27
JP2005520786A (ja) 2005-07-14
YU24004A (sh) 2006-08-17
CA2457563A1 (en) 2003-03-27
HUP0500238A2 (hu) 2005-05-30
CN1555271A (zh) 2004-12-15
EP1427349A2 (en) 2004-06-16
US20080003201A1 (en) 2008-01-03
WO2003024354A3 (en) 2004-02-05
PL374123A1 (en) 2005-10-03
HRP20040282A2 (en) 2004-08-31
KR20040044942A (ko) 2004-05-31
NZ531526A (en) 2007-05-31
US20030129161A1 (en) 2003-07-10

Similar Documents

Publication Publication Date Title
MXPA04002490A (es) Interleucina-12 como adyuvante de vacuna veterinaria.
MXPA01007760A (es) Compuesto adyuvante inmunologico.
WO2003011223A3 (en) Immunomodulatory compounds and methods of use thereof
BR9912177A (pt) Epìtopos de célula auxiliar t artificiais como imunoestimuladores para imunógenos de peptìdeo sintéticos
HK1072264A1 (en) Synthetic peptide vaccines for hiv: the cbd epitope as an effective immunogen to elicit broadly neutralizing antibodies against hiv
HK1044484A1 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide.
PT2364724E (pt) Composição de vacina compreendendo um adjuvante de saponina
HK1038507A1 (en) Influenza virus vaccine composition
GB0025577D0 (en) Vaccine
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
WO2002034119A3 (en) Vaccine immunotherapy for immune suppressed patients
MXPA04000680A (es) Vacuna para virus west nile.
HU9601466D0 (en) Adjuvants for viral vaccines
WO2001097841A3 (en) Qs-21 and il-12 as an adjuvant combination
AU2003212170A1 (en) Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof
WO2003083083A3 (en) Methods of using flt3-ligand in immunization protocols
EA200800917A1 (ru) Адъюванты для вакцин
AU3478393A (en) Vaccine containing acemannan as an adjuvant
MY141983A (en) Hepatitis b virus surface antigen as a mucosal immunoenhancer, resulting formulations
WO2002004497A3 (en) Multiple antigenic peptides immunogenic against streptococcus pneumoniae
WO2003040163A3 (en) Immunomodulating saponins, a method for their preparation and their use for vaccines

Legal Events

Date Code Title Description
FA Abandonment or withdrawal